tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Oct 1;9(11)
fac509.
doi: 10.1093/ofid/ofac509. eCollection 2022 Nov.
Discriminatory Ability of Gas Chromatography-Ion Mobility Spectrometry to Identify Patients Hospitalized With COVID-19 and Predict Prognosis
Joshua Nazareth[SUP] 1 2 [/SUP], Daniel Pan[SUP] 1 2 [/SUP], Jee Whang Kim[SUP] 1 3 [/SUP], Jack Leach[SUP] 4 [/SUP], James G Brosnan[SUP] 4 [/SUP], Adam Ahmed[SUP] 4 [/SUP], Emma Brodrick[SUP] 5 [/SUP], Paul Bird[SUP] 6 [/SUP], Alfian Wicaksono[SUP] 7 [/SUP], Emma Daulton[SUP] 7 [/SUP], Julian W Tang[SUP] 1 6 [/SUP], Caroline Williams[SUP] 1 2 [/SUP], Pranabashis Haldar[SUP] 1 3 [/SUP], James A Covington[SUP] 7 [/SUP], Manish Pareek[SUP] 1 2 [/SUP], Amandip Sahota[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Rapid diagnostic and prognostic tests for coronavirus disease (COVID-19) are urgently required. We aimed to evaluate the diagnostic and prognostic ability of breath analysis using gas chromatography-ion mobility spectrometry (GC-IMS) in hospitalized patients with COVID-19.
Methods: Between February and May 2021, we took 1 breath sample for analysis using GC-IMS from participants who were admitted to the hospital for COVID-19, participants who were admitted to the hospital for other respiratory infections, and symptom-free controls, at the University Hospitals of Leicester NHS Trust, United Kingdom. Demographic, clinical, and radiological data, including requirement for continuous positive airway pressure (CPAP) ventilation as a marker for severe disease in the COVID-19 group, were collected.
Results: A total of 113 participants were recruited into the study. Seventy-two (64%) were diagnosed with COVID-19, 20 (18%) were diagnosed with another respiratory infection, and 21 (19%) were healthy controls. Differentiation between participants with COVID-19 and those with other respiratory tract infections with GC-IMS was highly accurate (sensitivity/specificity, 0.80/0.88; area under the receiver operating characteristics curve [AUROC], 0.85; 95% CI, 0.74-0.96). GC-IMS was also moderately accurate at identifying those who subsequently required CPAP (sensitivity/specificity, 0.62/0.80; AUROC, 0.70; 95% CI, 0.53-0.87).
Conclusions: GC-IMS shows promise as both a diagnostic tool and a predictor of prognosis in hospitalized patients with COVID-19 and should be assessed further in larger studies.
Keywords: COVID-19; diagnosis; respiratory virus; volatile organic compounds.
. 2022 Oct 1;9(11)
fac509.doi: 10.1093/ofid/ofac509. eCollection 2022 Nov.
Discriminatory Ability of Gas Chromatography-Ion Mobility Spectrometry to Identify Patients Hospitalized With COVID-19 and Predict Prognosis
Joshua Nazareth[SUP] 1 2 [/SUP], Daniel Pan[SUP] 1 2 [/SUP], Jee Whang Kim[SUP] 1 3 [/SUP], Jack Leach[SUP] 4 [/SUP], James G Brosnan[SUP] 4 [/SUP], Adam Ahmed[SUP] 4 [/SUP], Emma Brodrick[SUP] 5 [/SUP], Paul Bird[SUP] 6 [/SUP], Alfian Wicaksono[SUP] 7 [/SUP], Emma Daulton[SUP] 7 [/SUP], Julian W Tang[SUP] 1 6 [/SUP], Caroline Williams[SUP] 1 2 [/SUP], Pranabashis Haldar[SUP] 1 3 [/SUP], James A Covington[SUP] 7 [/SUP], Manish Pareek[SUP] 1 2 [/SUP], Amandip Sahota[SUP] 2 [/SUP]
Affiliations
- PMID: 36345428
- PMCID: PMC9619573
- DOI: 10.1093/ofid/ofac509
Abstract
Background: Rapid diagnostic and prognostic tests for coronavirus disease (COVID-19) are urgently required. We aimed to evaluate the diagnostic and prognostic ability of breath analysis using gas chromatography-ion mobility spectrometry (GC-IMS) in hospitalized patients with COVID-19.
Methods: Between February and May 2021, we took 1 breath sample for analysis using GC-IMS from participants who were admitted to the hospital for COVID-19, participants who were admitted to the hospital for other respiratory infections, and symptom-free controls, at the University Hospitals of Leicester NHS Trust, United Kingdom. Demographic, clinical, and radiological data, including requirement for continuous positive airway pressure (CPAP) ventilation as a marker for severe disease in the COVID-19 group, were collected.
Results: A total of 113 participants were recruited into the study. Seventy-two (64%) were diagnosed with COVID-19, 20 (18%) were diagnosed with another respiratory infection, and 21 (19%) were healthy controls. Differentiation between participants with COVID-19 and those with other respiratory tract infections with GC-IMS was highly accurate (sensitivity/specificity, 0.80/0.88; area under the receiver operating characteristics curve [AUROC], 0.85; 95% CI, 0.74-0.96). GC-IMS was also moderately accurate at identifying those who subsequently required CPAP (sensitivity/specificity, 0.62/0.80; AUROC, 0.70; 95% CI, 0.53-0.87).
Conclusions: GC-IMS shows promise as both a diagnostic tool and a predictor of prognosis in hospitalized patients with COVID-19 and should be assessed further in larger studies.
Keywords: COVID-19; diagnosis; respiratory virus; volatile organic compounds.